Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

F Robbins

Showing results (191-200 of 258) with videos related to

Pageof 26
Sort By:
Human Gene Therapy|May 1, 2008
Adoptive cell therapy for patients with melanoma, using tumor-infiltrating lymphocytes genetically engineered to secrete interleukin-2Bianca Heemskerk, Ke Liu, Mark E Dudley, et al.
Science (New York, N.Y.)|April 15, 2017
Landscape of immunogenic tumor antigens in successful immunotherapy of virally induced epithelial cancerSanja Stevanović, Anna Pasetto, Sarah R Helman, et al.
The New England Journal of Medicine|December 14, 2016
T-Cell Transfer Therapy Targeting Mutant KRAS in CancerEric Tran, Paul F Robbins, Yong-Chen Lu, et al.
Nature Medicine|May 7, 2013
Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cellsPaul F Robbins, Yong-Chen Lu, Mona El-Gamil, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|November 28, 2017
An Efficient Single-Cell RNA-Seq Approach to Identify Neoantigen-Specific T Cell ReceptorsYong-Chen Lu, Zhili Zheng, Paul F Robbins, et al.
Cancer Immunology, Immunotherapy : CII|August 5, 2008
Recognition of NY-ESO-1+ tumor cells by engineered lymphocytes is enhanced by improved vector design and epigenetic modulation of tumor antigen expressionJennifer A Wargo, Paul F Robbins, Yong Li, et al.
Journal of Immunology (Baltimore, Md. : 1950)|May 22, 2013
Mutated PPP1R3B is recognized by T cells used to treat a melanoma patient who experienced a durable complete tumor regressionYong-Chen Lu, Xin Yao, Yong F Li, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|May 11, 2016
Isolation and Characterization of an HLA-DPB1*04: 01-restricted MAGE-A3 T-Cell Receptor for Cancer ImmunotherapyXin Yao, Yong-Chen Lu, Linda L Parker, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 3, 2014
Efficient identification of mutated cancer antigens recognized by T cells associated with durable tumor regressionsYong-Chen Lu, Xin Yao, Jessica S Crystal, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|September 16, 2003
Cell transfer therapy for cancer: lessons from sequential treatments of a patient with metastatic melanomaSteven A Rosenberg, James C Yang, Paul F Robbins, et al.
Pageof 26

Showing results (191-200 of 258) with videos related to

Sort By:
Pageof 26
Human Gene Therapy|May 1, 2008
Adoptive cell therapy for patients with melanoma, using tumor-infiltrating lymphocytes genetically engineered to secrete interleukin-2Bianca Heemskerk, Ke Liu, Mark E Dudley, et al.
Science (New York, N.Y.)|April 15, 2017
Landscape of immunogenic tumor antigens in successful immunotherapy of virally induced epithelial cancerSanja Stevanović, Anna Pasetto, Sarah R Helman, et al.
The New England Journal of Medicine|December 14, 2016
T-Cell Transfer Therapy Targeting Mutant KRAS in CancerEric Tran, Paul F Robbins, Yong-Chen Lu, et al.
Nature Medicine|May 7, 2013
Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cellsPaul F Robbins, Yong-Chen Lu, Mona El-Gamil, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|November 28, 2017
An Efficient Single-Cell RNA-Seq Approach to Identify Neoantigen-Specific T Cell ReceptorsYong-Chen Lu, Zhili Zheng, Paul F Robbins, et al.
Cancer Immunology, Immunotherapy : CII|August 5, 2008
Recognition of NY-ESO-1+ tumor cells by engineered lymphocytes is enhanced by improved vector design and epigenetic modulation of tumor antigen expressionJennifer A Wargo, Paul F Robbins, Yong Li, et al.
Journal of Immunology (Baltimore, Md. : 1950)|May 22, 2013
Mutated PPP1R3B is recognized by T cells used to treat a melanoma patient who experienced a durable complete tumor regressionYong-Chen Lu, Xin Yao, Yong F Li, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|May 11, 2016
Isolation and Characterization of an HLA-DPB1*04: 01-restricted MAGE-A3 T-Cell Receptor for Cancer ImmunotherapyXin Yao, Yong-Chen Lu, Linda L Parker, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 3, 2014
Efficient identification of mutated cancer antigens recognized by T cells associated with durable tumor regressionsYong-Chen Lu, Xin Yao, Jessica S Crystal, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|September 16, 2003
Cell transfer therapy for cancer: lessons from sequential treatments of a patient with metastatic melanomaSteven A Rosenberg, James C Yang, Paul F Robbins, et al.
Pageof 26